Mynd life sciences announces proposed share issuance to remove debenture and $3.440 m in debt on business

Vancouver, british columbia--(newsfile corp. - november 12, 2024) - mynd life sciences (cse: mynd) (otcqb: myndf) ("mynd" or the "company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that subject to regulatory approval, it is proposing to issue 4 million shares @ 0.71 per share to move $3.5 million from its balance sheet, including the full restructure of an outstanding debenture on the business. "we are pleased to announce this important agreement to restructure our balance sheet to enhance both current and prospective shareholder value and to align with our strategic goals of optimizing our capital structure," mynd life sciences ceo, colin campbell commented.
MYND Ratings Summary
MYND Quant Ranking